APEI Stock Analysis: American Public Education | NASDAQ
Education & Training Services | NASDAQ, USA | Market Cap: 837m USD | 12M Return: 40.7% | US02913V1035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.1M
Qual. Beats: 4
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
American Public Education, Inc. (APEI) is a US-based provider of online and campus-based postsecondary education, operating through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 181 degree programs, 110 certificate programs, and four diploma programs spanning public service-oriented fields such as nursing, national security, military studies, intelligence, and homeland security, as well as traditional academic disciplines including business, health science, information technology, justice studies, education, and liberal arts.
APEI also delivers career learning and leadership training to the federal civilian workforce in person and online, and through Hondros College of Nursing provides pre-licensure nursing education, including a diploma in practical nursing, an associate degree in nursing, and a bachelor of science in nursing. The company is headquartered in Charles Town, West Virginia, was incorporated in 1991, and trades as a small-cap stock within the US for-profit Education Services sub-industry, a sector that historically serves a disproportionate share of military-affiliated and working-adult learners seeking flexible, career-oriented degree pathways.
- APUS military enrollment growth drives segment revenue
- Title IV and GI Bill funding regulations impact federal aid dependence
- Rasmussen University and Hondros nursing enrollment trends shape margins
| Net Income: 45.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 29.28% < 20% (prev 23.59%; Δ 5.69% < -1%) |
| CFO/TA 0.16 > 3% & CFO 85.6m > Net Income 45.7m |
| Net Debt (136.8m) to EBITDA (83.0m): 1.65 < 3 |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.8m) vs 12m ago 4.30% < -2% |
| Gross Margin: 54.61% > 18% (prev 53.39%; Δ 1.22% > 0.5%) |
| Asset Turnover: 124.3% > 50% (prev 119.9%; Δ 4.32% > 0%) |
| Interest Coverage Ratio: 18.60 > 6 (EBIT TTM 66.8m / Interest Expense TTM 3.59m) |
| A: 0.36 (Total Current Assets 282.5m - Total Current Liabilities 87.0m) / Total Assets 537.7m |
| B: 0.01 (Retained Earnings 6.00m / Total Assets 537.7m) |
| C: 0.12 (EBIT TTM 66.8m / Avg Total Assets 537.6m) |
| D: 1.40 (Book Value of Equity 314.1m / Total Liabilities 223.7m) |
| Altman-Z'' = 4.73 = AA |
| DSRI: 0.95 (Receivables 39.6m/40.1m, Revenue 668.0m/644.5m) |
| GMI: 0.98 (GM 53.39% / 54.61%) |
| AQI: 0.93 (AQ_t 0.24 / AQ_t-1 0.26) |
| SGI: 1.04 (Revenue 668.0m / 644.5m) |
| TATA: -0.07 (NI 45.7m - CFO 85.6m) / TA 537.7m) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of September 09, 2026, the stock is trading at USD 45.36 with a total of 165,938 shares traded. Over the past week, the price has changed by -0.64%, over one month by -4.28%, over three months by -12.52% and over the past year by +40.65%.
Current recommended Stop Loss: 43.10 (which is 5% or 1.2 ATR below the current price).
American Public Education has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy APEI.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.8 | 38.5% |
P/E Trailing = 18.5223
P/E Forward = 15.015
P/S = 1.2534
P/B = 2.6696
P/EG = 1.0013
Revenue TTM = 668.0m USD
EBIT TTM = 66.8m USD
EBITDA TTM = 83.0m USD
Long Term Debt = 94.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.1m USD (from shortTermDebt, last quarter)
Debt = 213.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 65.2m
Net Debt = 136.8m USD (calculated: Debt 213.0m - CCE 76.3m)
Enterprise Value = 974.1m USD (837.3m + Debt 213.0m - CCE 76.3m)
Interest Coverage Ratio = 18.60 (Ebit TTM 66.8m / Interest Expense TTM 3.59m)
EV/FCF = 13.90x (Enterprise Value 974.1m / FCF TTM 70.1m)
FCF Yield = 7.19% (FCF TTM 70.1m / Enterprise Value 974.1m)
FCF Margin = 10.49% (FCF TTM 70.1m / Revenue TTM 668.0m)
Net Margin = 6.84% (Net Income TTM 45.7m / Revenue TTM 668.0m)
Gross Margin = 54.61% ((Revenue TTM 668.0m - Cost of Revenue TTM 303.2m) / Revenue TTM)
Gross Margin QoQ = 55.37% (prev 54.91%)
Tobins Q-Ratio = 1.81 (Enterprise Value 974.1m / Total Assets 537.7m)
Interest Expense / Debt = 1.69% (Interest Expense 3.59m / Debt 213.0m)
Taxrate = 23.67% (14.2m / 59.8m)
NOPAT = 51.0m (EBIT 66.8m * (1 - 23.67%))
Current Ratio = 3.25 (Total Current Assets 282.5m / Total Current Liabilities 87.0m)
Debt / Equity = 0.68 (Debt 213.0m / totalStockholderEquity, last quarter 314.1m)
Debt / EBITDA = 1.65 (Net Debt 136.8m / EBITDA 83.0m)
Debt / FCF = 1.95 (Net Debt 136.8m / FCF TTM 70.1m)
Total Stockholder Equity = 298.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.50% (Net Income 45.7m / Total Assets 537.7m)
RoE = 15.30% (Net Income TTM 45.7m / Total Stockholder Equity 298.6m)
RoCE = 17.00% (EBIT 66.8m / Capital Employed (Equity 298.6m + L.T.Debt 94.7m))
RoIC = 11.91% (NOPAT 51.0m / Invested Capital 428.5m)
WACC = 5.00% (E(837.3m)/V(1.05b) * Re(5.95%) + D(213.0m)/V(1.05b) * Rd(1.69%) * (1-Tc(0.24)))
Discount Rate = 5.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.71 | Cagr: 2.46%
[DCF] Terminal Value 77.97% ; FCFF base≈62.1m ; Y1≈71.2m ; Y5≈104.8m
[DCF] Fair Price = 78.71 (EV 1.58b - Net Debt 136.8m = Equity 1.44b / Shares 18.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.00 | # QB: 4
Revenue Correlation: 98.42 | Revenue CAGR: 4.30% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.61 | Chg30d=-1.61% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=3.02 | Chg30d=+0.33% | Revisions=+40% | GrowthEPS=+37.9% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=3.76 | Chg30d=-0.27% | Revisions=+25% | GrowthEPS=+24.3% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +12% (up=3, down=2)